Author:
Oesch Gabriela,Bozarth Xiuhua Liang
Subject
Neurology (clinical),Neurology
Reference26 articles.
1. Evaluation of long-term safety, tolerability, and behavioral outcomes with adjunctive rufinamide in pediatric patients (≥1 to <4 years old) with Lennox-Gastaut syndrome: Final results from randomized study 303;Arzimanoglou;Eur. J. Paediatr. Neurol.,2019
2. Safety and pharmacokinetic profile of rufinamide in pediatric patients aged less than 4 years with Lennox-Gastaut syndrome: An interim analysis from a multicenter, randomized, active-controlled, open-label study;Arzimanoglou;Eur. J. Paediatr. Neurol.,2016
3. Progress report on new antiepileptic drugs: a summary of the eigth Eilat conference (EILAT VIII), 2007;Bialer;Epilepsy Res.,2007
4. A randomized, double-blind, placebo-controlled, parallel-group study of rufinamide as adjunctive therapy for refractory partial-onset seizures;Biton;Epilepsia,2011
5. Rufinamide for the adjunctive treatment of partial seizures in adults and adolescents: A randomized placebo-controlled trial;Brodie;Epilepsia,2009
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献